EPO and primary hyperparathyroidism: In endocrine pathologies such as primary hyperparathyroidism (PHPT), EPO resistance is mediated by elevated fibroblast growth factor 23 (FGF23), a hormone implicated in phosphate homeostasis, inflammation, and erythropoiesis [139,140].